2,3,5,4'‑tetrahydroxy‑stilbene‑2‑O‑β‑D‑glucoside attenuates methionine and choline‑deficient diet‑induced non‑alcoholic fatty liver disease

Han,Mingnuan; Zhang,Ting; Gu,Wen; Yang,Xingxin; Zhao,Ronghua; Yu,Jie

doi:10.3892/etm.2018.6300

2,3,5,4'‑tetrahydroxy‑stilbene‑2‑O‑β‑D‑glucoside attenuates methionine and choline‑deficient diet‑induced non‑alcoholic fatty liver disease

Authors:
- Mingnuan Han
- Ting Zhang
- Wen Gu
- Xingxin Yang
- Ronghua Zhao
- Jie Yu
View Affiliations

Affiliations: College of Pharmaceutical Science, Yunnan University of Traditional Chinese Medicine, Kunming, Yunnan 650500, P.R. China
Published online on: June 13, 2018 https://doi.org/10.3892/etm.2018.6300
Pages: 1087-1094
Copyright: © Han et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous studies have suggested that 2,3,5,4'‑tetrahydroxy‑stilbene‑2‑O‑β‑D‑glucoside (TSG) prevents progression of non‑alcoholic fatty liver disease (NAFLD) induced by high‑fat diet. The present study aimed to evaluate whether TSG could reverse NAFLD induced by a methionine and choline‑deficient (MCD) diet and identify the possible mechanism of action. C57BL6/J mice were fed a MCD diet and were treated with TSG, fenofibrate, and resveratrol for 9 weeks. Regulatory effects of several cytokines and enzymes, including Nod‑like receptor protein 3, apoptosis‑associated speck‑like protein containing a C-terminal caspase recruitment domain (ASC), caspase‑1, interleukin (IL)‑18, IL‑1β, and gut microbiota balance were investigated. TSG significantly reduced NAFLD biochemical indexes, including total cholesterol, triglyceride, low density lipoprotein cholesterol, very low density lipoprotein cholesterol, aspartate aminotransferase and free fatty acid. Middle dosage (TSG.M, 35 mg/kg) of TSG reduced the expression of ASC and caspase‑1. Furthermore, TSG displayed gut microbiota regulatory effects on MCD‑induced NAFLD mice. The results of the present study suggested that TSG prevented the occurrence and development of MCD diet‑induced NAFLD. The data further indicated that TSG may serve as a promising lead compound that may aid with intervention in NAFLD therapy.

View Figures

View References

1	Ishii KA and Takamura T: Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) and nutrition. Clin Calcium. 26:363–367. 2016.(In Japanese). PubMed/NCBI
2	Moghaddasifar I, Lankarani KB, Moosazadeh M, Afshari M, Ghaemi A, Aliramezany M, Gharebagh Afsar R and Malary M: Prevalence of non-alcoholic fatty liver disease and its related factors in Iran. Int J Organ Transplant Med. 7:149–160. 2016.PubMed/NCBI
3	Ruhl CE and Everhart JE: Fatty liver indices in the multiethnic united states national health and nutrition examination survey. Aliment Pharm Therap. 41:65–76. 2015. View Article : Google Scholar
4	Fung J, Lee CK, Chan M, Seto WK, Lai CL and Yuen MF: Hong Kong Liver Health Census Study Group: High prevalence of non-alcoholic fatty liver disease in the Chinese-results from the Hong Kong liver health census. Liver Int. 58:542–549. 2015. View Article : Google Scholar
5	Iftikhar R, Kamran SM, Sher F and Wahla MS: Prevalence of non alcoholic fatty liver disease in patients with metabolic syndrome. PAFMJ. 65:616–619. 2015.
6	Mehal WZ: The Gordian Knot of dysbiosis, obesity and NAFLD. Nat Rev GastroHepat. 10:637–644. 2013.
7	Manan B and Saraswat VA: Gut-liver axis: Role of inflammasomes. J Clin Exp Hepatol. 3:141–149. 2013. View Article : Google Scholar : PubMed/NCBI
8	Strowig T, Henao-Mejia J, Elinav E and Flavell R: Inflammasomes in health and disease. Nature. 481:278–286. 2012. View Article : Google Scholar : PubMed/NCBI
9	Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, Thaiss CA, Kau AL, Eisenbarth SC, Jurczak MJ, et al: Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 482:179–185. 2012. View Article : Google Scholar : PubMed/NCBI
10	Dixon LJ, Berk M, Thapaliya S, Papouchado BG and Feldstein AE: Caspase-1-mediated regulation of fibrogenesis in diet-induced steatohepatitis. Lab Invest. 92:713–723. 2012. View Article : Google Scholar : PubMed/NCBI
11	Petrasek J, Bala S, Csak T, Lippai D, Kodys K, Menashy V, Barrieau M, Min SY, Kurt-Jones EA and Szabo G: IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice. J Clin Invest. 122:3476–3489. 2012. View Article : Google Scholar : PubMed/NCBI
12	Csak T, Ganz M, Pespisa J, Kodys K, Dolganiuc A and Szabo G: Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology. 54:133–144. 2011. View Article : Google Scholar : PubMed/NCBI
13	Wree A, Mcgeough MD, Peña CA, Schlattjan M, Li H, Inzaugarat ME, Messer K, Canbay A, Hoffman HM and Feldstein AE: NLRP3 inflammasome activation is required for fibrosis development in NAFLD. J Mol Med (Berl). 92:1069–1082. 2014. View Article : Google Scholar : PubMed/NCBI
14	Lin P, Lu J, Wang Y, Gu W, Yu J and Zhao RH: Naturally occurring stilbenoid TSG reverses non-alcoholic fatty liver diseases via gut-liver axis. PLoS One. 10:01403462015. View Article : Google Scholar
15	Wang W, He Y, Lin P, Li Y, Sun R, Gu W, Yu J and Zhao R: In vitro effects of active components of Polygoni Multiflori Radix on enzymes involved in the lipid metabolism. J Ethnopharmacol. 153:763–770. 2014. View Article : Google Scholar : PubMed/NCBI
16	Lin P, He YR, Lu JM, Li N, Wang WG, Gu W, Yu J and Zhao RH: In vivo lipid regulation mechanism of polygoni multiflori radix in high-fat diet fed rats. Evid Based Complement Alternat Med. 2014:6420582014. View Article : Google Scholar : PubMed/NCBI
17	Li N, Chen Z, Mao XJ, Yu J and Zhao RH: Effects of lipid regulation using raw and processed radix polygoni multiflori in rats fed a high-fat diet. Evid Based Complement Alternat Med. 2012:3291712012. View Article : Google Scholar : PubMed/NCBI
18	Wang M, Zhao R, Wang W, Mao X and Yu J: Lipid regulation effects of polygoni multiflori radix, its processed products and its major substances on steatosis human liver cell line L02. J Ethnopharmacol. 139:287–293. 2012. View Article : Google Scholar : PubMed/NCBI
19	Yang SJ and Lim Y: Resveratrol ameliorates hepatic metaflammation and inhibits NLRP3 inflammasome activation. Metabolism. 63:693–701. 2014. View Article : Google Scholar : PubMed/NCBI
20	CaporasoJ G, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, Fierer N, Peña AG, Goodrich JK, Gordon JI, et al: QIIME allows analysis of high-throughput community sequencing data. Nat Methods. 7:335–336. 2010. View Article : Google Scholar : PubMed/NCBI
21	Magoč T and Salzberg SL: FLASH: Fast length adjustment of short reads to improve genome assemblies. Bioinformatics. 27:2957–2963. 2011. View Article : Google Scholar : PubMed/NCBI
22	Yao ZM and Vance DE: Reduction in VLDL, but not HDL, in plasma of rats deficient in choline. Biochem Cell Biol. 68:552–558. 1990. View Article : Google Scholar : PubMed/NCBI
23	Bieghs V and Trautwein C: The innate immune response during liver inflammation and metabolic disease. Trends Immunol. 34:446–452. 2013. View Article : Google Scholar : PubMed/NCBI
24	Okubo H, Sakoda H, Kushiyama A, Fujishiro M, Nakatsu Y, Fukushima T, Matsunaga Y, Kamata H, Asahara T, Yoshida Y, et al: Lactobacillus casei strain Shirota protects against nonalcoholic steatohepatitis development in a rodent model. Am J Physiol Gastrointest Liver Physiol. 305:G911–G918. 2013. View Article : Google Scholar : PubMed/NCBI
25	Endo H, Niioka M, Kobayashi N, Tanaka M and Watanabe T: Butyrate-producing probiotics reduce nonalcoholic fatty liver disease progression in rats: New insight into the probiotics for the gut-liver axis. PLoS One. 8:00633882013. View Article : Google Scholar
26	Miura K and Ohnishi H: Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease. World J Gastroentero. 20:7381–7391. 2014. View Article : Google Scholar
27	Lee SM, Han HW and Yim SY: Beneficial effects of soy milk and fiber on high cholesterol diet-induced alteration of gut microbiota and inflammatory gene expression in rats. Food Funct. 6:492–500. 2015. View Article : Google Scholar : PubMed/NCBI
28	Harris JK, El Kasmi KC, Anderson AL, Devereaux MW, Fillon SA, Robertson CE, Wagner BD, Stevens MJ, Pace NR and Sokol RJ: Specific microbiome changes in a mouse model of parenteral nutrition associated liver injury and intestinal inflammation. PLoS One. 9:01103962014. View Article : Google Scholar
29	Del Chierico F, Gnani D, Vernocchi P, Petrucca A, Alisi A, Dallapiccola B, Nobili V and Lorenza P: Meta-omic platforms to assist in the understanding of NAFLD gut microbiota alterations: tools and applications. Int J Mol Sci. 15:684–711. 2014. View Article : Google Scholar : PubMed/NCBI
30	Koch KN and Müller A: Helicobacter pylori activates the TLR2/NLRP3/caspase-1/IL-18 axis to induce regulatory T-cells, establish persistent infection and promote tolerance to allergens. Gut Microbes. 6:382–387. 2015. View Article : Google Scholar : PubMed/NCBI
31	Barlow GM, Yu A and Mathur R: Role of the gut microbiome in obesity and diabetes mellitus. Nutr Clin Pract. 30:787–797. 2015. View Article : Google Scholar : PubMed/NCBI
32	Everarda A, Belzerb C, Geurtsa L, Ouwerkerk JP, Druart C, Bindels LB, Guiot Y, Derrien M, Muccioli GG, Delzenne NM, et al: Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci USA. 110:9066–9071. 2013. View Article : Google Scholar : PubMed/NCBI
33	Itagaki H, Shimizu K, Morikawa S, Ogawa K and Ezaki T: Morphological and functional characterization of non-alcoholic fatty liver disease induced by a methionine-choline-deficient diet in C57BL/6 mice. Int J Clin Exp Patho. 6:2683–2696. 2013.
34	Leclercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ and Robertson GR: CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest. 105:1067–1075. 2000. View Article : Google Scholar : PubMed/NCBI
35	Oliveira CP, da Costa Gayotto LC, Tatai C, Della Bina BI, Janiszewski M, Lima ES, Abdalla DS, Lopasso FP, Laurindo FR and Laudanna AA: Oxidative stress in the pathogenesis of nonalcoholic fatty liver disease, in rats fed with a choline-deficient diet. J Cell Mol Med. 6:399–406. 2002. View Article : Google Scholar : PubMed/NCBI
36	Wree A, Eguchi A, McGeough MD, Pena CA, Johnson CD, Canbay A, Hoffman HM and Feldstein AE: NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice. Hepatology. 59:898–910. 2014. View Article : Google Scholar : PubMed/NCBI
37	Fukui H: Gut microbiota and host reaction in liver diseases. Microorganisms. 3:759–791. 2015. View Article : Google Scholar : PubMed/NCBI
38	Bawa M and Saraswat V: Gut-liver axis: Role of inflammasomes. J Clin Exp Hepatol. 3:141–149. 2013. View Article : Google Scholar : PubMed/NCBI
39	Capiralla H, Vingtdeux V, Zhao H, Sankowski R, Al-Abed Y, Davies P and Marambaud P: Resveratrol mitigates lipopolysaccharide- and Aβ-mediated microglial inflammation by inhibiting the TLR4/NF-κB/STAT signaling cascade. J Neurochem. 120:461–472. 2012. View Article : Google Scholar : PubMed/NCBI
40	Yi CO, Jeon BT, Shin HJ, Jeong EA, Chang KC, Lee JE, Lee DH, Kim HJ, Kang SS, Cho GJ, et al: Resveratrol activates AMPK and suppresses LPS-induced NF-κB-dependent COX-2 activation in RAW 264.7 macrophage cells. Anat Cell Biol. 44:194–203. 2011. View Article : Google Scholar : PubMed/NCBI
41	Huang C, Wang Y, Wang J, Yao W, Chen X and Zhang W: TSG (2,3,4′,5-tetrahydroxystilbene 2-O-β-D-glucoside) suppresses induction of pro-inflammatory factors by attenuating the binding activity of nuclear factor-κB in microglia. J Neuroinflammation. 10:1292013. View Article : Google Scholar : PubMed/NCBI
42	Saiko P, Szakmary A, Jaeger W and Szekeres T: Resveratrol and its analogs: Defense against cancer, coronary disease and neurodegenerative maladies or just a fad? Mutat Res. 658:68–94. 2008. View Article : Google Scholar : PubMed/NCBI
43	Chao JF, Li HT, Cheng KW, Yu MS, Chang RC and Wang M: Protective effects of pinostilbene, a resveratrol methylated derivative, against 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells. J Nutr Biochem. 21:482–489. 2010. View Article : Google Scholar : PubMed/NCBI
44	Larrosa M, Tomé-Carneiro J, Yáñez-Gascón MJ, Alcántara D, Selma MV, Beltrán D, García-Conesa MT, Urbán C, Lucas R, Tomás-Barberán F, et al: Preventive oral treatment with resveratrol pro-prodrugs drastically reduce colon inflammation in rodents. J Med Chem. 53:7365–7376. 2010. View Article : Google Scholar : PubMed/NCBI
45	Zhou XX, Yang Q, Xie YH, Sun JY, Qiu PC, Cao W and Wang SW: Protective effect of tetrahydroxystilbene glucoside against D-galactose inducedaging process in mice. Phytochem Lett. 6:372–378. 2013. View Article : Google Scholar